Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals - 08/04/22
Doi : 10.1016/j.jinf.2022.01.002
Sian Faustini a 
, Adrian Shields a, c , Gemma Banham b, c , Nadezhda Wall b, c , Saly Al-Taei a , Chloe Tanner a, Zahra Ahmed a , Elena Efstathiou a , Neal Townsend a , Margaret Goodall a , Tim Plant a , Marisol Perez-Toledo a , Aleksandra Jasiulewicz a , Ruth Price e , James McLaughlin f , John Farnan g , Julie Moore e , Louise Robertson e , Andrew Nesbit e , Grace Curry e , Amy Black g , Adam Cunningham a , Lorraine Harper c, d , Tara Moore e, f, h , Mark Drayson a , Alex Richter a, c, 1, ⁎
, Adrian Shields a, c , Gemma Banham b, c , Nadezhda Wall b, c , Saly Al-Taei a , Chloe Tanner a, Zahra Ahmed a , Elena Efstathiou a , Neal Townsend a , Margaret Goodall a , Tim Plant a , Marisol Perez-Toledo a , Aleksandra Jasiulewicz a , Ruth Price e , James McLaughlin f , John Farnan g , Julie Moore e , Louise Robertson e , Andrew Nesbit e , Grace Curry e , Amy Black g , Adam Cunningham a , Lorraine Harper c, d , Tara Moore e, f, h , Mark Drayson a , Alex Richter a, c, 1, ⁎ a Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
b Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
c University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
d Institute of Applied Health, University of Birmingham, Birmingham, United Kingdom
e Biomedical Sciences Research Institute, Ulster University, Northern Ireland
f Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
g The Group Surgery, 257 North Queen Street, Belfast, Northern, Ireland
h Avellino labs USA 1505 Adams Drive Menlo Park, CA 94025 USA
⁎Corresponding author at: Clinical Immunology Service, Institute of Immunology and Immunotherapy, Medical School, University of Birmingham, Edgbaston, B15 2TT.Clinical Immunology Service, Institute of Immunology and ImmunotherapyMedical School, University of BirminghamEdgbastonB15 2TT
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | IgG anti-SARS-CoV-2 Omicron spike glycoprotein antibodies were detected in 100% of health care workers, a real world population attending general practice for vaccination and haemodialysis patients 4 weeks after a third SARS-CoV-2 vaccine dose (Pfizer-BioNtech 162b2). |
• | Against both Delta and Omicron variants, antibody levels were higher in the cohort who had previously received two doses of Astrazeneca ChAdOx1 nCoV-19 vaccine than two doses of Pfizer-Biontech 162b2. |
• | Prior to this third vaccine dose and 6 months post second vaccine dose, there was evidence of significant waning of antibody reactivity against Delta and Omicron variants of concern, particularly in individuals initially receiving two doses of Astrazeneca ChAdOx1 nCoV-19. |
Keywords : COVID-19, SARS-CoV-2, Haemodialysis, Chronic kidney disease, vaccination, antibody response, Variants of Concern, Cross reactivity, Delta, Omicron
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 84 - N° 4
P. 579-613 - avril 2022 Retour au numéro
Article précédent
- Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
- Xiaohua Gong, Liuqing Yang, Jie Li, Jiaqi Zhang, Lanlan Wei, Guoguo Ye, Yimin Tang, Yujing Jiang, Jianhuan Li, Yuanlong Lin, Fuxiang Wang, Hongzhou Lu, Yingxia Liu
- Control of COVID-19 in China likely reduced the burden of multiple other infectious diseases
- Ji-Ming Chen, Yi-Qing Chen, Ying-Xue Sun
Bienvenue sur EM-consulte, la référence des professionnels de santé.